Absorption, liver first-pass effect, pharmacokinetics and tissue distribution of calycosin-7-O-beta-D-glucopyranoside (C7G) and its major active metabolite, calycosin, following oral administration of C7G in rats by LC-MS/MS
文献类型:期刊论文
作者 | Tian, Xiaoting1,2; Chen, Shuoji1,2,3; Zhang, Yuanyuan4; Chen, Luying1,2; Guo, Xiaozhen1,2; Xu, Zhou1,2; Liu, Huan1,2; Hu, Pei1,2; Chen, Zhenyuan1,2; Li, Zhixiong1,2![]() |
刊名 | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
![]() |
出版日期 | 2018-01-30 |
卷号 | 148页码:350-354 |
关键词 | Calycosin-7-O-beta-D-glucopyranoside Calycosin Pharmacokinetics Liver first-pass effect Tissue distribution |
ISSN号 | 0731-7085 |
DOI | 10.1016/j.jpba.2017.10.027 |
文献子类 | Article |
英文摘要 | Previously, we discovered calycosin, an extensively distributed metabolite of Calycosin-7-O-beta-nglucopyranoside (C7G), elicited stronger anti-virus activity than C7G. However, the pharmacokinetics and tissue distribution of C7G and calycosin remained obscure on C7G treatments. In this study, a liquid chromatography tandem mass spectrometry method was established and validated for the simultaneous determination of C7G and calycosin, and it was applied to the pharmacokinetics and tissue distribution of C7G and calycosin following oral administration of C7G at 120 mg/kg in rats. Consequently, the exposure of C7G and calycosin was both similarly low in the systemic plasma, but the levels of calycosin were 53.5 folds higher than that of C7G in the portal vein plasma, corresponding to the liver extraction ratio (ER) of C7G and calycosin at 0.3% and 98.5% respectively. Therefore, our results revealed that liver first-pass effect played the predominant role in the poor circulating levels of calycosin on C7G treatments, whereas the intestinal first-pass effect was predominant for those of C7G. In contrast to no observation of C7G, the calycosin levels were 212.1, 30.5 and 4.7 folds higher in the liver, kidney and heart than its circulating levels, respectively. The high tissue distribution of calycosin provided new hints and evidences to the pharmacological mechanisms of C7G and Astragali Radix. (C) 2017 Elsevier B.V. All rights reserved. |
WOS关键词 | ANTIVIRAL ACTIVITIES ; CELLS ; IDENTIFICATION |
资助项目 | National Natural Science Foundation of China[81374052] ; Shanghai Science and Technology Foundation[14401900700] ; National Natural Science Foundation for Young Scientists of China[81603280] ; National Natural Science Foundation for Young Scientists of China[81602998] |
WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
语种 | 英语 |
WOS记录号 | WOS:000417771700043 |
出版者 | ELSEVIER SCIENCE BV |
源URL | [http://119.78.100.183/handle/2S10ELR8/279943] ![]() |
专题 | 上海中药现代化研究中心 |
通讯作者 | Li, Zhixiong; Huang, Chenggang |
作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China; 3.Shanghai Normal Univ, Coll Life & Environm Sci, Shanghai 201203, Peoples R China; 4.Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China |
推荐引用方式 GB/T 7714 | Tian, Xiaoting,Chen, Shuoji,Zhang, Yuanyuan,et al. Absorption, liver first-pass effect, pharmacokinetics and tissue distribution of calycosin-7-O-beta-D-glucopyranoside (C7G) and its major active metabolite, calycosin, following oral administration of C7G in rats by LC-MS/MS[J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,2018,148:350-354. |
APA | Tian, Xiaoting.,Chen, Shuoji.,Zhang, Yuanyuan.,Chen, Luying.,Guo, Xiaozhen.,...&Huang, Chenggang.(2018).Absorption, liver first-pass effect, pharmacokinetics and tissue distribution of calycosin-7-O-beta-D-glucopyranoside (C7G) and its major active metabolite, calycosin, following oral administration of C7G in rats by LC-MS/MS.JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,148,350-354. |
MLA | Tian, Xiaoting,et al."Absorption, liver first-pass effect, pharmacokinetics and tissue distribution of calycosin-7-O-beta-D-glucopyranoside (C7G) and its major active metabolite, calycosin, following oral administration of C7G in rats by LC-MS/MS".JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 148(2018):350-354. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。